PET MRI in Coronary Artery Disease
Combined Magnetic Resonance Coronary Angiography and Positron Emission Tomography in Patients With Coronary Artery Disease
1 other identifier
observational
16
1 country
1
Brief Summary
This study will assess the use of position emission tomography/magnetic resonance imaging (PET/MRI) using ultra-small-superparamagnetic particles of iron oxide (USPIO) as a contrast agent in patients with coronary artery disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2018
CompletedFirst Submitted
Initial submission to the registry
February 23, 2018
CompletedFirst Posted
Study publicly available on registry
March 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2024
CompletedMay 21, 2024
May 1, 2024
5.2 years
February 23, 2018
May 20, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
PET/MRI findings
The primary endpoint will be the difference in MRI and PET characteristics of atherosclerotic plaques in patients with and without recent acute coronary syndromes.
Immediately after PET/MRI scan
Study Arms (3)
Healthy volunteers
Healthy volunteers to undergo MRI using USPIO contrast
Stable coronary artery disease
Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation
Recent acute coronary syndrome
Patients with recent (3 months) type 1 myocardial infarction
Interventions
Eligibility Criteria
Healthy volunteers to undergo MRI. Patients with stable coronary artery disease or recent acute myocardial infarction to undergo PET/MRI
You may qualify if:
- Healthy volunteers to undergo MRI imaging will be over the age of 18 years and able to provide informed consent.
- Patients with coronary artery disease to undergo PET/MRI will have multi-vessel disease (≥2 vessel coronary artery disease with ≥ 50% cross-sectional luminal stenosis).
- able to provide informed consent
- over the age of 40 years
You may not qualify if:
- inability or unwillingness to undergo magnetic resonance imaging or positron emission tomography
- renal failure (Serum creatinine \>200 umol/L or estimated glomerular filtration rate \<30 mL/min
- hepatic failure
- pregnancy
- inability to provide informed consent
- contraindications to undergoing MRI scanning
- contraindications to contrast agents not included above including evidence of iron overload, known allergy to constituents of the contrast agents, and anaemia not caused by iron deficiency
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Royal Infirmary of Edinburgh
Edinburgh, Scotland, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michelle Williams
University of Edinburgh
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 23, 2018
First Posted
March 1, 2018
Study Start
February 1, 2018
Primary Completion
May 1, 2023
Study Completion
January 31, 2024
Last Updated
May 21, 2024
Record last verified: 2024-05